JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study

Jaeeun Lee; Seunghyun Lewis Kwon; Jinhee Park; Hyuna Bae; Hyerim Lee; Geun-Yong Kwon

doi:10.24171/j.phrp.2023.0182

Articles

Page Path

Brief Report

JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study

Jaeeun Lee^1,2

, Seunghyun Lewis Kwon^1,2,3

, Jinhee Park^1,2

, Hyuna Bae^1,2

, Hyerim Lee^2,4

, Geun-Yong Kwon^2,4

Osong Public Health and Research Perspectives 2023;14(5):433-438.
Published online: October 18, 2023

DOI: https://doi.org/10.24171/j.phrp.2023.0182

¹Division of Immunization, Bureau of Healthcare Safety and Immunization, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea

²Central Disease Control Headquarters of Monkeypox, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea

³KDI School of Public Policy and Management, Sejong, Republic of Korea

⁴Division of Immunization Planning, Bureau of Healthcare Safety and Immunization, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea

Corresponding author: Geun-Yong Kwon Division of Immunization Planning, Bureau of Healthcare Safety and Immunization, Korea Disease Control and Prevention Agency, 200 OsongSaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju 28159, Republic of Korea E-mail: ego1002@korea.kr

• Received: June 30, 2023 • Revised: September 4, 2023 • Accepted: September 8, 2023

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

4,123 Views
77 Download
7 Web of Science
6 Crossref
6 Scopus

Full Article

Download PDF

Abstract
Graphical abstract
Introduction
Materials and Methods
Results
Discussion
HIGHLIGHTS
Article information
References

Abstract

Objectives
With the recent global mpox outbreak, the JYNNEOS vaccine (Modified Vaccinia Ankara-Bavarian Nordic) was developed as a third-generation smallpox vaccine and initially favored for mpox immunization. Vaccine-associated side effects contribute to vaccine hesitancy. Consequently, tracking adverse events post-immunization is crucial for safety management. This study used data from the national active vaccine safety surveillance conducted in Korea from August 25 to November 24, 2022 to detect potential safety signals and adverse events.
Methods
Data on health conditions following vaccination were gathered from web-based surveys and reported via active surveillance through the Immunization Registry Information System. This follow-up system functioned via a text message link, surveying adverse events and health conditions beginning on the second day post-vaccination. Information about specific adverse events, including both local and systemic reactions, was collected.
Results
The study included 86 healthcare workers who had received at least 1 dose of the JYNNEOS vaccine. Among the respondents, 79.1% reported experiencing at least 1 adverse event, with the majority being local reactions at the injection site. The incidence of adverse events was higher following the first dose (67.9%) than after the second dose (34.4%). The most frequently reported adverse event for both doses was mild pain at the injection site.
Conclusion
The study provides crucial information on the safety of the JYNNEOS vaccine, demonstrating that most adverse events were manageable and predominantly localized to the injection site. Nonetheless, additional research is needed on the safety of various vaccine administration techniques and the vaccine's effects on broader demographics.
Keywords: Adverse events; Mpox; Safety; Vaccination; Vaccines

Graphical abstract

Introduction

The first case of mpox in Korea was confirmed on June 22, 2022. In response, the Korea Disease Control and Prevention Agency (KDCA) sought emergency use authorization for JYNNEOS, a third-generation smallpox vaccine derived from a live, attenuated orthopoxvirus, known as modified vaccine Ankara. By July 1, 2022, the Ministry of Food and Drug Safety (MFDS) had approved the emergency use of JYNNEOS, following a review by the Korea Orphan and Essential Drug Center. The vaccine was administered to adults aged ≥18 years as a 2-dose series (0.5 mL per dose) via subcutaneous injection, with doses given at least 28 days apart. The KDCA guidelines also specify that individuals who have previously been vaccinated against smallpox should receive only 1 dose [1]. Given the potential for exposure among laboratory and healthcare personnel due to their occupational activities, many countries recommend prioritizing these workers for vaccine access [2-4]. Accordingly, the KDCA’s mpox vaccination strategy primarily targets individuals who have known or presumed exposure to mpox, or those who are at high risk for occupational exposure, such as healthcare workers, laboratory workers, and Epidemiological Investigation Officers [1-5]. This report presents an analysis of adverse event data collected from healthcare workers who received the JYNNEOS vaccination between August 25 and November 24, 2022.

Materials and Methods

Data Collection

Between August 25 and November 24, 2022, a total of 99 individuals, specifically those at occupational risk of exposure, voluntarily received at least 1 dose of the JYNNEOS vaccine at a healthcare center in Korea. For the analysis, we included 86 individuals who reported their health conditions after receiving at least 1 dose. The KDCA actively monitored the safety of the JYNNEOS vaccine. The day after their vaccination, individuals received text message notifications containing a health survey, which asked about potential adverse events for the 7 days following vaccination. This questionnaire was based on the Korean MFDS’s guideline for evaluating the severity of adverse events in vaccine clinical trials, and was used to evaluate serious adverse events [2]. The survey assessed the severity of 12 symptoms and signs. In each survey, participants were asked if they were experiencing symptoms, and the severity of each symptom was classified as either mild, moderate (symptoms that do not interfere with daily life), or severe (symptoms that interfere with daily activities and necessitate emergency visits). During the surveillance period, all health conditions were recorded, even for those without symptoms.

Study Design

This study was carried out as a prospective, self-reported survey of adverse events over a period of 121 days, from August 2022 to November 2022. The data reported were analyzed according to age group (20−29, 30−39, 40−49, 50 years and above), dosage, severity of adverse events, and symptoms indicative of potential adverse events. Descriptive statistics were utilized to detail the adverse events experienced by the participants. All analyses were performed using SAS ver. 9.4 (SAS Institute).

IRB Approval

All activities described in this study were carried out under the supervision and approval of the public health authority. In line with government regulations, informed consent was duly obtained. The study, which involved text message-based surveillance, was granted an exemption from review by the Institutional Review Board of the KDCA (2022-08-09-PE-A).

Results

After applying the exclusion criteria detailed in Figure 1, we included a total of 86 individuals who reported their health conditions following at least 1 dose of the vaccine. Of these 86 respondents, 70 (81.4%) were fully vaccinated with a second dose, while 16 (18.6%) were partially vaccinated with just 1 dose due to the presence of a smallpox vaccination scar, which is a clear indicator of previous vaccination. All of the vaccine recipients were healthcare workers, including Epidemiological Investigation Officers. Among them, 51.2% were women, and 38.4% were aged between 30 and 39 years. A summary of the characteristics of the vaccine recipients is presented in Table 1.

Adverse Events by Signs and Symptoms

Of all the reports, 79.1% documented at least 1 adverse event (Table 1). The most commonly reported adverse events were local reactions, including pain, swelling, and erythema at the injection site. Systemic reactions such as pyrexia, fatigue, headache, and myalgia were reported infrequently. Regarding gastrointestinal disorders, there were no reports of nausea, but sporadic cases of diarrhea were noted, ranging from a minimum of 1 case (1.6%) to a maximum of 2 cases (2.4%). Skin disorders (excluding those at the injection site) were very rare, with a minimum of 1 case (1.6%) and a maximum of 7 cases (8.3%). These symptoms were mild and did not interfere with the individuals’ daily activities. There were no reports of severe neurological disorders; however, mild symptoms, such as sweating and dizziness, were reported, ranging from a minimum of 1 case (1.6%) to a maximum of 2 cases (2.4%) (Table 2).

Incidence of Adverse Events between First and Second Vaccine Doses

The incidence of adverse events following the first dose was 67.9%, and 34.4% after the second dose. The risk seems to be relatively lower after the administration of the second dose (Table 3). The most commonly reported adverse events for both the first and second doses were similar. The majority of these adverse events were local reactions, with the most common being pain, swelling, and erythema at the injection site. Following the first dose, the incidence of pain at the injection site was over 64.3%. Most of these were instances of mild pain that did not interfere with daily activities (n=51, 60.7%), and very few were reported as pain that interfered with daily activities (n=4, 4.8%). For the second dose, nearly half (49.2%) reported mild pain at the injection site that did not interfere with daily life. The incidence of swelling and erythema at the injection site after the first and second doses were relatively similar. However, the size of the affected areas with swelling and erythema appeared to be larger after the second dose. No serious adverse events were reported following either the first or second vaccinations. Table 2 presents the reporting rates for the first and second doses by symptom.

Discussion

We conducted the first study aimed at identifying adverse events in healthcare workers in Korea who had received a minimum of 1 dose of the JYNNEOS vaccine. The web-based survey was dispatched the day following their vaccination, and it required reporting for at least 1 day after each dose. The majority of adverse events were reactions at the injection site, and no new worrisome symptoms were identified. This aligns with the findings of previous studies [7,8].

This study offers timely insights into the safety of mpox vaccination. However, it should be noted that the findings detailed in this report are subject to several limitations, which are addressed below alongside recommendations for best practices in future research. First and foremost, only reactions at the subcutaneous injection site were observed. In a previous study, vaccine administration errors were reported more frequently following intradermal administration than subcutaneous administration of the JYNNEOS vaccine [7]. Given that the mpox vaccination was administered solely subcutaneously during the study period, data on adverse events following alternative routes of administration is limited. Further research is necessary to examine the effects of different injection techniques. This could contribute to a more comprehensive understanding of the safety of the method, particularly in comparison to intradermal injection.

Secondly, the study population was composed exclusively of healthy adults. Throughout the study period, mpox vaccinations were restricted and recommended solely for individuals with a high likelihood of exposure, such as those with occupational risks. The recipients of the vaccine were either healthcare workers, laboratory workers, or epidemiological investigation officers. As a result, there was a lack of diversity among the research participants. Concerns about vaccine safety could also hinder vaccination efforts; further studies are suggested to ensure the safety of vaccination for vulnerable populations, such as those with HIV or within specific age groups [9].

The safety data from the KDCA for the JYNNEOS vaccine indicate that the subcutaneous administration of the JYNNEOS mpox vaccine is safe. It further recommends the use of the JYNNEOS vaccine in accordance with KDCA guidelines. The KDCA will persist in monitoring any adverse events to provide vaccination recommendations that prioritize safety.

HIGHLIGHTS

• The safety of the JYNNEOS vaccine in response to an mpox outbreak was investigated in Korea from August to November 2022.

• Post-vaccination health conditions were monitored utilizing web-based surveys and the Immunization Registry Information System.

• Among the 86 healthcare workers included in the study, 79.1% reported experiencing adverse events, primarily localized at the injection site, and a higher incidence was observed after the first dose.

• Most of these events were manageable, but further research on diverse populations and administration methods is needed.

Article information

Ethics Approval

All activities described in this study were reviewed and conducted with authorization from the public health authority. Informed consent was collected in accordance with government regulations, and the study with the text message-based surveillance was exempted from review by the Institutional Review Board of KDCA (2022-08-09-PE-A).

Conflicts of Interest

The authors have no conflicts of interest to declare.

Funding

None.

Availability of Data

The data used in this study are protected under the Personal Information Protection Act.

Authors’ Contributions

Conceptualization: JL, JP, HB, GYK; Data curation: JL, JP, HB; Formal analysis: JL, JP, HB; Investigation: JL, JP, HB; Methodology: all authors; Supervision: GYK; Validation: JL, JP, HB, GYK; Visualization: JL; Writing–original draft: JL; Writing–review & editing: all authors. All authors read and approved the final manuscript.

Figure 1.

Flowchart illustrating the exclusion of sample subjects from the pool of vaccinated recipients.

Between August 25 and November 24, 2022, JYNNEOS vaccinations were administered to 99 individuals. Thirteen participants who did not report any consultations for any of the listed adverse events were excluded. Additionally, we had to exclude those with missing reports for each dose. After excluding non-respondents (n=2), the analysis of the first dose included 84 individuals. For the analysis of the second dose, we excluded those who had not received the second dose (n=16) and non-respondents (n=9), leaving 61 individuals included in the final analysis.

JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study

Table 1.

Characteristics of JYNNEOS vaccine recipients with reports submitted to Immunization Registry Information System after vaccination (n=86), Republic of Korea, August 25 to November 24, 2022

Table 1.
Characteristic	No. of reports (%)^a)
Sex
Male	42 (48.8)
Female	44 (51.2)
Age group (y)
20−29	12 (14.0)
30−39	33 (38.4)
40−49	28 (32.6)
≥50	13 (15.1)
Dose in series
First	86 (100.0)
Second^b)	70 (81.4)
Route of administration
Subcutaneous	86 (100.0)

^a)The reported data included all recipients who had received at least 1 dose and submitted a report.

^b)Individuals (n=16) who had been vaccinated in the past against smallpox were excluded.

Table 2.

Reporting rates by local and systematic reactions. Republic of Korea, August 25 to November 24, 2022

Table 2.
Health event	First dose (n=84)	Second dose (n=61)
Local reaction (injection site)
Pain
None	29 (34.5)	21 (34.4)
Mild pain that does not interfere with daily life	51 (60.7)	30 (49.2)
Interference with activities of daily living	4 (4.8)	10 (16.4)
ED visit or hospitalization	0 (0)	0 (0)
Swelling
None or with a diameter of 2.5 cm or less	62 (73.8)	32 (52.5)
With a diameter of 2.5−5 cm	17 (20.2)	19 (31.1)
With a diameter of 5.1−10 cm or difficulty moving arm	5 (6.0)	7 (11.5)
With a diameter of 5.1−10 cm or degree of interference with activities of daily	0 (0)	3 (4.9)
Erythema (redness)
None or with a diameter of 2.5 cm or less	65 (77.4)	31 (50.8)
With a diameter of 2.5−5 cm	15 (17.9)	17 (27.9)
With a diameter of 5.1−10 cm	4 (4.8)	10 (16.4)
With a diameter of 10 cm or more	0 (0)	3 -(4.9)
Systematic reaction
Pyrexia
None	79 (94.0)	55 (90.2)
Fever of 38.4 ℃ or less	5 (6.0)	5 (8.2)
Fever of 38.5−38.9 ℃	0 (0)	1 (1.6)
Fever of 39.0−40.0 ℃	0 (0)	0 (0)
Fever of 40.0 ℃ or less	0 (0)	0 (0)
Dyspnea
None	84 (100.0)	61 (100.0)
Shortness of breathing not interfering with daily life	0 (0)	0 (0)
ED visit due to breathing difficulty	0 (0)	0 (0)
Fatigue
None	62 (73.8)	41 (67.2)
Mild fatigue, but does not interfere with daily life	16 (19.0)	15 (24.6)
Interference with activities of daily living	6 (7.1)	5 (8.2)
ED visit or hospitalization	0 (0)	0 (0)
Headache
None	72 (85.7)	52 (85.2)
Mild headaches that do not require medical attention	6 (7.1)	3 (4.9)
Managing pain with medicine; does not interfere with daily life	4 (4.8)	6 (9.8)
Pain is not manageable with medicine; interference with activities of daily life	2 (2.4)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Myalgia
None	65 (77.4)	47 (77.0)
Mild: does not interfere with daily life	15 (17.9)	11 (18.0)
Interference with activities of daily living	4 (4.8)	3 (4.9)
ED visit or hospitalization	0 (0)	0 (0)
Gastrointestinal disorders
Nausea
None	84 (100.0)	61 (100.0)
Mild nausea: does not interfere with daily life	0 (0)	0 (0)
Vomiting 1−2 times/d	0 (0)	0 (0)
Vomiting more than 3 times/d	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Diarrhea
None	81 (96.4)	60 (98.4)
1−2 times/d	2 (2.4)	1 (1.6)
More than 6 times/day or received medical treatment	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Skin disorders (other than the injection site)
Urticarial or erythema
None	82 (97.6)	60 (98.4)
Mild: does not interfere with daily life	2 (2.4)	1 (1.6)
Interference with activities of daily living	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Swelling
None	77 (91.7)	59 (96.7)
Mild: does not interfere with daily life	7 (8.3)	2 (3.3)
Interference with activities of daily living	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Neurologic disorders
Syncope or seizure
None	82 (97.6)	60 (98.4)
Sweating and dizziness	2 (2.4)	1 (1.6)
Loss of consciousness	0 (0)	0 (0)
Injury due to syncope	0 (0)	0 (0)
Seizure	0 (0)	0 (0)
Febrile seizure	0 (0)	0 (0)
Unconscious for a day or more after seizure	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)

Data are presented as n (%).

ED, emergency department.

Table 3.

Reporting rate for adverse health events reported, Republic of Korea, August 25 to November 24, 2022

Table 3.
Seriousness	Total (n=86)^a))	First dose (n=84)^b)	Second dose (n=61)^c)
No symptom	18 (20.9)	27 (32.1)	40 (65.6)
Non-serious	68 (79.1)	57 (67.9)	21 (34.4)
Serious	0 (0)	0 (0)	0 (0)

Non-serious events are when it does not meet any of the criteria for serious adverse events. Serious adverse events include symptoms that interfere with activities of daily living, and emergency visits.

^a)The total reported data includes the recipients among persons who had received at least 1 dose.

^b)The reported data for the first dose includes the recipients among persons who had received the first dose, and submitted a report to the survey.

^c)The reported data for the second dose includes the recipients among persons who had received the second dose, and submitted a report to the survey.

References

1. Korea Disease Control and Prevention Agency (KDCA). Guideline for mpox 3rd generation vaccination 4th ed. KDCA; 2023. Korean.
Article
PubMed
PMC
PDF
2. Thorsteinsdottir B, Madsen BE. Prioritizing health care workers and first responders for access to the COVID19 vaccine is not unethical, but both fair and effective: an ethical analysis. Scand J Trauma Resusc Emerg Med 2021;29:77.
PDF
3. Kwon SL, Ban S, Shin J, et al. Monkeypox vaccination in the Republic of Korea: identifying the high-risk target group. J Korean Med Sci 2022;37:e239.
Article
PubMed
PMC
PDF
4. World Health Organization (WHO). Considerations for monkeypox vaccination acceptance and demand in the WHO European Region: 10 October 2022. WHO; 2022.
Article
PubMed
PMC
PDF
5. Korea Disease Control and Prevention Agency (KDCA). Guideline for mpox response 5-1 ed. KDCA; 2023. Korean.
Article
PubMed
PMC
PDF
6. Ministry of Food and Drug Safety (MFDS). Guideline for evaluating the severity of adverse event in vaccine clinical trials. MFDS; 2011. Korean.
PDF
7. Duffy J, Marquez P, Moro P, et al. Safety monitoring of JYNNEOS vaccine during the 2022 mpox outbreak-United States, May 22-October 21, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1555−9.
PDF
8. Meo SA, Al-Masri AA, Klonoff DC, et al. Comparison of biological, pharmacological characteristics, indications, contraindications and adverse effects of JYNNEOS and ACAM2000 monkeypox vaccines. Vaccines (Basel) 2022;10:1971.
PDF
9. World Health Organization (WHO). Vaccines and immunization for monkeypox: interim guidance, 16 November 2022. WHO; 2022.
PDF

Cite

CITE

export

Copy Download

Format
XML Download

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study

Osong Public Health Res Perspect. 2023;14(5):433-438. Published online October 18, 2023

DOI: https://doi.org/10.24171/j.phrp.2023.0182

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
bib — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study

Osong Public Health Res Perspect. 2023;14(5):433-438. Published online October 18, 2023

DOI: https://doi.org/10.24171/j.phrp.2023.0182

Figure

COVID-19 infection among people with disabilities in 2021 prior to the Omicron-dominant period in the Republic of Korea: a cross-sectional study

JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study

Characteristic	No. of reports (%)^a)
Sex
Male	42 (48.8)
Female	44 (51.2)
Age group (y)
20−29	12 (14.0)
30−39	33 (38.4)
40−49	28 (32.6)
≥50	13 (15.1)
Dose in series
First	86 (100.0)
Second^b)	70 (81.4)
Route of administration
Subcutaneous	86 (100.0)

Health event	First dose (n=84)	Second dose (n=61)
Local reaction (injection site)
Pain
None	29 (34.5)	21 (34.4)
Mild pain that does not interfere with daily life	51 (60.7)	30 (49.2)
Interference with activities of daily living	4 (4.8)	10 (16.4)
ED visit or hospitalization	0 (0)	0 (0)
Swelling
None or with a diameter of 2.5 cm or less	62 (73.8)	32 (52.5)
With a diameter of 2.5−5 cm	17 (20.2)	19 (31.1)
With a diameter of 5.1−10 cm or difficulty moving arm	5 (6.0)	7 (11.5)
With a diameter of 5.1−10 cm or degree of interference with activities of daily	0 (0)	3 (4.9)
Erythema (redness)
None or with a diameter of 2.5 cm or less	65 (77.4)	31 (50.8)
With a diameter of 2.5−5 cm	15 (17.9)	17 (27.9)
With a diameter of 5.1−10 cm	4 (4.8)	10 (16.4)
With a diameter of 10 cm or more	0 (0)	3 -(4.9)
Systematic reaction
Pyrexia
None	79 (94.0)	55 (90.2)
Fever of 38.4 ℃ or less	5 (6.0)	5 (8.2)
Fever of 38.5−38.9 ℃	0 (0)	1 (1.6)
Fever of 39.0−40.0 ℃	0 (0)	0 (0)
Fever of 40.0 ℃ or less	0 (0)	0 (0)
Dyspnea
None	84 (100.0)	61 (100.0)
Shortness of breathing not interfering with daily life	0 (0)	0 (0)
ED visit due to breathing difficulty	0 (0)	0 (0)
Fatigue
None	62 (73.8)	41 (67.2)
Mild fatigue, but does not interfere with daily life	16 (19.0)	15 (24.6)
Interference with activities of daily living	6 (7.1)	5 (8.2)
ED visit or hospitalization	0 (0)	0 (0)
Headache
None	72 (85.7)	52 (85.2)
Mild headaches that do not require medical attention	6 (7.1)	3 (4.9)
Managing pain with medicine; does not interfere with daily life	4 (4.8)	6 (9.8)
Pain is not manageable with medicine; interference with activities of daily life	2 (2.4)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Myalgia
None	65 (77.4)	47 (77.0)
Mild: does not interfere with daily life	15 (17.9)	11 (18.0)
Interference with activities of daily living	4 (4.8)	3 (4.9)
ED visit or hospitalization	0 (0)	0 (0)
Gastrointestinal disorders
Nausea
None	84 (100.0)	61 (100.0)
Mild nausea: does not interfere with daily life	0 (0)	0 (0)
Vomiting 1−2 times/d	0 (0)	0 (0)
Vomiting more than 3 times/d	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Diarrhea
None	81 (96.4)	60 (98.4)
1−2 times/d	2 (2.4)	1 (1.6)
More than 6 times/day or received medical treatment	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Skin disorders (other than the injection site)
Urticarial or erythema
None	82 (97.6)	60 (98.4)
Mild: does not interfere with daily life	2 (2.4)	1 (1.6)
Interference with activities of daily living	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Swelling
None	77 (91.7)	59 (96.7)
Mild: does not interfere with daily life	7 (8.3)	2 (3.3)
Interference with activities of daily living	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)
Neurologic disorders
Syncope or seizure
None	82 (97.6)	60 (98.4)
Sweating and dizziness	2 (2.4)	1 (1.6)
Loss of consciousness	0 (0)	0 (0)
Injury due to syncope	0 (0)	0 (0)
Seizure	0 (0)	0 (0)
Febrile seizure	0 (0)	0 (0)
Unconscious for a day or more after seizure	0 (0)	0 (0)
ED visit or hospitalization	0 (0)	0 (0)

Seriousness	Total (n=86)^a))	First dose (n=84)^b)	Second dose (n=61)^c)
No symptom	18 (20.9)	27 (32.1)	40 (65.6)
Non-serious	68 (79.1)	57 (67.9)	21 (34.4)
Serious	0 (0)	0 (0)	0 (0)

Table 1. Characteristics of JYNNEOS vaccine recipients with reports submitted to Immunization Registry Information System after vaccination (n=86), Republic of Korea, August 25 to November 24, 2022
a)

The reported data included all recipients who had received at least 1 dose and submitted a report.

Individuals (n=16) who had been vaccinated in the past against smallpox were excluded.

Table 2. Reporting rates by local and systematic reactions. Republic of Korea, August 25 to November 24, 2022

Data are presented as n (%).

ED, emergency department.

Table 3. Reporting rate for adverse health events reported, Republic of Korea, August 25 to November 24, 2022

The total reported data includes the recipients among persons who had received at least 1 dose.

The reported data for the first dose includes the recipients among persons who had received the first dose, and submitted a report to the survey.

The reported data for the second dose includes the recipients among persons who had received the second dose, and submitted a report to the survey.

Articles

Page Path

JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study

Full Article

Abstract

Graphical abstract

Introduction

Materials and Methods

Data Collection

Study Design

IRB Approval

Results

Adverse Events by Signs and Symptoms

Incidence of Adverse Events between First and Second Vaccine Doses

Discussion

HIGHLIGHTS

Article information

References

Figure & Data

References

Citations

CITE

Download Citation

Format:

Include:

Figure

Related articles

Figure 1.

Graphical abstract

Table 1.

Table 2.

Table 3.

About

Browse articles

Editorial policies

For authors